SPS
ABUS icon

Susquehanna Portfolio Strategies’s Arbutus Biopharma ABUS Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.7K Buy
+18,820
New +$82.3K ﹤0.01% 939

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Susquehanna Portfolio Strategies's ABUS Position: Q1 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Arbutus Biopharma (ABUS) in Q1 2026: 18,820 shares worth $84.7K. The stake represents ﹤0.01% of the portfolio and ranks #939 among its holdings.

167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Susquehanna Portfolio Strategies held 18,820 shares of Arbutus Biopharma worth $84.7K as of Q1 2026.
  • Arbutus Biopharma was a new Susquehanna Portfolio Strategies position in Q1 2026.
  • Arbutus Biopharma made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #939 holding.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.